{"id":85131,"date":"2023-11-14T10:45:55","date_gmt":"2023-11-14T09:45:55","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=85131"},"modified":"2023-11-14T10:46:41","modified_gmt":"2023-11-14T09:46:41","slug":"andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/","title":{"rendered":"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom"},"content":{"rendered":"<p>Andera Partners, a leading European private equity player, today announces that it is co-leading a \u20ac67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with participation from Revelation Partners, Indaco Venture Partners, Panak\u00e8s Partners, X-Gen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.<\/p>\n<p>The proceeds will be used to continue advancing and expanding Nouscom\u2019s wholly owned clinical pipeline to achieve multiple clinical value catalysts, including:<\/p>\n<ul>\n<li>Readout from Nouscom\u2019s ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf vaccine targeting 209 shared neoantigens, in combination with pembrolizumab for the treatment of Mismatch Repair\/Microsatellite Instable (dMMR\/MSI) Metastatic Colorectal Cancer (mCRC).<\/li>\n<li>Final readout from the ongoing Phase 1b study and advancement of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer before it occurs. LS carriers have a genetic predisposition to and consequently higher risk of developing certain cancers. Promising initial results from this study were reported in a Late-breaking Abstract at the recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting \u2013 see press release here<\/li>\n<li>Completion of a Phase 1b study evaluating NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs.<\/li>\n<\/ul>\n<p><strong>Dr. Marina Udier, Chief Executive Officer of Nouscom<\/strong>, said: <em>\u201cThis oversubscribed financing, in what is a challenging environment for all biotech companies, is testament to the faith that new and existing investors place in Nouscom and our best-in-class technology. I am constantly inspired by the relentless drive our team exhibits on a daily basis to advancing our innovative medicines for the benefit of cancer patients. This financing will allow us to further accelerate development across our wholly owned clinical <\/em><em>portfolio reporting multiple clinical trial readouts including from our ongoing randomized Phase 2 clinical trial with NOUS-209. These Phase 2 data, if positive, have the potential to position Nouscom\u2019s neoantigen based cancer vaccines amongst the most thrilling developments in the field.\u201d<\/em><\/p>\n<p><strong>Dr. Goran Ando, Independent Chairman of Nouscom<\/strong>, said: <em>\u201cIn conjunction with the financing, I am delighted to welcome all our new investors to the company and Sofia, Thibaut and Hakan from Andera, Bpifrance and M Ventures, respectively, to our Board of Directors. Together, with the experience of our existing Board Members, I look forward to their contributions as Nouscom navigates the next exciting steps in its journey.\u201d<\/em><\/p>\n<p><strong>Dr. Sofia Ioannidou, Partner of Andera Partners<\/strong>, said: <em>\u201cWe at Andera are delighted to support Marina and her team in their mission to advance the development of their innovative cancer treatments for patients. We believe that the robustness of the clinical results generated so far positions Nouscom as one of the leading biotech companies in the vibrant neoantigen cancer vaccine space. We look forward to supporting the company towards the further clinical validation of its platform.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners, a leading European private equity player, today announces that it is co-leading a \u20ac67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-85131","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners, a leading European private equity player, today announces that it is co-leading a \u20ac67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-14T09:45:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-14T09:46:41+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom\",\"datePublished\":\"2023-11-14T09:45:55+00:00\",\"dateModified\":\"2023-11-14T09:46:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\"},\"wordCount\":545,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\",\"name\":\"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2023-11-14T09:45:55+00:00\",\"dateModified\":\"2023-11-14T09:46:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/","og_locale":"en_US","og_type":"article","og_title":"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom - ANDERA PARTNERS","og_description":"Andera Partners, a leading European private equity player, today announces that it is co-leading a \u20ac67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2023-11-14T09:45:55+00:00","article_modified_time":"2023-11-14T09:46:41+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom","datePublished":"2023-11-14T09:45:55+00:00","dateModified":"2023-11-14T09:46:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/"},"wordCount":545,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/","name":"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2023-11-14T09:45:55+00:00","dateModified":"2023-11-14T09:46:41+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-co-leads-a-e67-5-million-72-million-oversubscribed-series-c-round-for-cancer-immunotherapy-company-nouscom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera Partners co-leads a \u20ac67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/85131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=85131"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/85131\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=85131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=85131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}